6.545

0.77% 0.045

Acrivon Therapeutics Inc (ACRV)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$6.50

Offen:

$6.5

24-Stunden-Volumen:

10,755

Relative Volume:

0.13

Marktkapitalisierung:

$202.85M

Einnahmen:

Nettoeinkommen (Verlust:

$-69.00M

KGV:

-2.619

EPS:

-2.499

Netto-Cashflow:

$-55.26M

1W Leistung:

-17.30%

1M Leistung:

-18.63%

6M Leistung:

-20.22%

1J Leistung:

+80.44%

1-Tages-Spanne:

$6.43

$6.68

1-Wochen-Bereich:

$6.1097

$8.35

52-Wochen-Spanne:

$3.19

$11.90

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Firmenname

Acrivon Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

617-207-8979

Adresse

480 ARSENAL WAY, SUITE 100, WATERTOWN

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ACRV's Discussions on Twitter

Vergleichen Sie ACRV mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACRV	6.55	202.85M	0	-69.00M	-55.26M	-2.499
VRTX	449.86	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	746.01	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	591.92	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	245.88	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.22	24.89B	3.30B	-501.07M	1.03B	11.54

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-05-08	Eingeleitet	BMO Capital Markets	Outperform
2023-04-27	Eingeleitet	Ladenburg Thalmann	Buy
2023-04-20	Eingeleitet	H.C. Wainwright	Buy
2022-12-12	Eingeleitet	Cowen	Outperform
2022-12-12	Eingeleitet	Jefferies	Buy
2022-12-12	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten

Nov 18, 2024

HC Wainwright Issues Pessimistic Outlook for ACRV Earnings - MarketBeat

Nov 18, 2024

Nov 17, 2024

We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Simply Wall St

Nov 17, 2024

Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright - Defense World

Nov 17, 2024

BMO Capital Markets Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $27.00 - Defense World

Nov 17, 2024

When (ACRV) Moves Investors should Listen - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results - TipRanks

Nov 14, 2024

Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments - Investing.com

Nov 14, 2024

Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets - MarketBeat

Nov 14, 2024

Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright - MarketBeat

Nov 14, 2024

Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments By Investing.com - Investing.com South Africa

Nov 14, 2024

Nov 13, 2024

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Nov 13, 2024

Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position | ACRV Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Nov 09, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Average PT from Analysts - Defense World

Nov 09, 2024

Nov 06, 2024

Trend Tracker for (ACRV) - Stock Traders Daily

Nov 06, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Nov 06, 2024

Oct 30, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World

Oct 30, 2024

Oct 29, 2024

Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com Canada

Oct 29, 2024

Oct 28, 2024

Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 26, 2024

(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 26, 2024

Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews

Oct 26, 2024

Oct 19, 2024

Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World

Oct 19, 2024

Oct 17, 2024

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire

Oct 17, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat

Oct 17, 2024

Oct 16, 2024

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

(ACRV) Investment Analysis and Advice - Stock Traders Daily

Oct 15, 2024

Oct 12, 2024

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance

Oct 12, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Oct 12, 2024

Oct 11, 2024

Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com

Oct 11, 2024

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire

Oct 11, 2024

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel - The Bakersfield Californian

Oct 11, 2024

Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Marketscreener.com

Oct 11, 2024

Oct 02, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Bought by Marshall Wace LLP - MarketBeat

Oct 02, 2024

Sep 30, 2024

Perceptive Advisors LLC Acquires 2,353,000 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - MarketBeat

Sep 30, 2024

Sep 28, 2024

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expands By 24.3% - MarketBeat

Sep 28, 2024

Sep 27, 2024

Wall Street SWOT: Acrivon Therapeutics stock shows promise amid oncology challenges - Investing.com

Sep 27, 2024

Sep 24, 2024

The Potential Rise in the Price of ACM Research Inc (ACMR) following insiders activity - Knox Daily

Sep 24, 2024

DRW Securities LLC Invests $287,000 in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World

Sep 24, 2024

Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch

Sep 24, 2024

You might want to take a look at ACM Research Inc (ACMR) now - SETE News

Sep 24, 2024

When the Price of (ACRV) Talks, People Listen - Stock Traders Daily

Sep 24, 2024

Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance

Sep 24, 2024

Benjamin F. Edwards & Company Inc. Has $847,000 Stock Position in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World

Sep 24, 2024

Sep 23, 2024

Ladenburg Thalmann Upgrades Acrivon Therapeutics Inc (ACRV) to a Buy from a Neutral - Knox Daily

Sep 23, 2024

Deeper Dive: Understanding Acrivon Therapeutics Inc (ACRV) Through its Various Ratios - The Dwinnex

Sep 23, 2024

Brighton Jones LLC Makes New Investment in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World

Sep 23, 2024